What is Psoriatic Arthritis Treatment Market?
About 7.5 million Americans have psoriasis and around 30 percent of these people develop psoriatic arthritis. Psoriatic arthritis is a form of inflammatory arthritis that combines the swollen, sore joints of arthritis with psoriasis. Its primary symptoms involve joint pain, stiffness and swelling. It can affect any part of the body such as the fingertips and spine and can range from relatively mild to severe. There is no cure for psoriatic arthritis and the treatment used for controlling symptoms and preventing damage to joints.
The market study is being classified and major geographies with country level break-up.
Novartis International AG (Switzerland), Abbvie (United States), Eli Lilly and Company (United States), Roche Holding AG (Switzerland), Merck & Co. (United States), Amgen (United States), Bristol Myers Squibb (United States), Celgene Corporation (United States), Janssen Pharmaceutica (Belgium) and Bausch Health Companies Inc. (Canada) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Psoriatic Arthritis Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Psoriatic Arthritis Treatment market by Type, Application and Region.
On the basis of geography, the market of Psoriatic Arthritis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Psoriatic Arthritis among People
- Increased Number of Diagnostic Centres
- Rise in the Healthcare Infrastructure in Developing Regions
- Technological Advancements in The Medical Science
- Increasing Consumer Awareness
- No Complete Cure for Psoriatic Arthritis
- Side Effects of the Medicines
- Growth in the Healthcare Industry Worldwide
- Increasing Demand for Cost-Effective Medicines
- Stringent Government Rules and Regulations
In August 2019, Amgen has announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities.
Key Target AudiencePsoriatic Arthritis Treatment Providers, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase